secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiromic Biopharma, Inc. (—)
CIK:        0001792581
Form:       8-K
Filed at:   2023-08-29T23:59:59+00:00
Accession:  0001558370-23-015324
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiromic BioPharma issues $2.4M 25% senior secured convertible note due 2024
---------------------------------------------------------------------------

- Principal $2.4M, 25% annual interest, matures Aug 25, 2024.
- Convertible into common stock at $5.00 per share, subject to 9.99% beneficial ownership cap.
- Secured by all of the Company’s intellectual property and fixtures/equipment.
- Issued in a private placement exempt from registration under Section 4(a)(2) of the Securities Act.
- Company must obtain stockholder approval for conversion shares exceeding Nasdaq share cap (19.99% of outstanding).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1792581/000155837023015324/0001558370-23-015324-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1792581/000155837023015324/krbp-20230825x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-015324

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer